The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).
 
Jean-Christophe Pignon
No Relationships to Disclose
 
Opeyemi Jegede
No Relationships to Disclose
 
Sachet A Shukla
Stock and Other Ownership Interests - 152 Therapeutics; Agios; Celgene; Newlink Genetics
 
David A. Braun
Consulting or Advisory Role - Adept Field Solutions; Blueprint Partnership; Charles River Associates; Dedham Group; Defined Health; Insight Strategy; Octane Co.; Slingshot Insights; Trinity Group
 
Christine Horak
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Megan Wind-Rotolo
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Other Relationship - Huntsworth Health (I)
 
Yuko Ishii
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Agios; Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Takeda
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb
 
Paul J. Catalano
Consulting or Advisory Role - Lilly
 
Gordon J. Freeman
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Adaptimmune (I); Elstar Therapeutics (I); Origimed; SQZ Biotech (I); Surface Oncology (I); Xios Therapeutics
Research Funding - Bristol-Myers Squibb; Ipsen (I); Novartis (I); Quark (I); Roche/Genentech (I); UCB (I)
Patents, Royalties, Other Intellectual Property - Amplimmune/Astrazeneca; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Dako; EMD Serono; Merck; Novartis; Novartis (I); Pfizer (I); Roche/Genentech; Roche/Genentech (I)
 
Rebecca B Jennings
No Relationships to Disclose
 
Aguirre De Cubas
No Relationships to Disclose
 
Kimryn Rathmell
Stock and Other Ownership Interests - Caribou Publishing (I); Sitryx (I)
Honoraria - Calithera Biosciences (I); ImmuNext (I); Johnson & Johnson (I); Merck (I); Pfizer; Roche (I)
Consulting or Advisory Role - Calithera Biosciences (I); Calithera Biosciences (I); ImmuNext (I); Johnson & Johnson (I); Pfizer (I); Roche (I)
Research Funding - AstraZeneca; Bristol-Myers Squibb (Inst); Calithera Biosciences (I); Calithera Biosciences (Inst); Incyte (I); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche; Tempus (I); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - ClearCode34 Risk prediction biomarker for kidney cancer; hERV 3-2 expression as a biomarker of response to immunotherapy
Travel, Accommodations, Expenses - Calithera Biosciences (I); Caribou Publishing; Johnson & Johnson (I); Merck (I); Pfizer (I); Roche (I)
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - Dana Farber Cancer Hospital; Kidney Cancer Association; NCCN
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Michael B. Atkins
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Acceleron Pharma; Aduro Biotech; Agenus; Array BioPharma; Arrowhead Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Glactone Pharma; Immunocore; Iovance Biotherapeutics; Merck; Newlink Genetics/Pharmatech; Novartis; Oncolys BioPharma; Pfizer; Surface Oncology; Werewolf Pharma; X4 Pharma
Research Funding - Bristol-Myers Squibb (Inst)
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; Bristol-Myers Squibb; EMD Serono; exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer; X4 Pharma
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Prometheus (Inst)
Other Relationship - Beth Israel Deaconess Medical Center; Various
 
Sabina Signoretti
Consulting or Advisory Role - AACR; AstraZeneca/MedImmune; Merck; NCI
Research Funding - AstraZeneca (Inst); Exelixis (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for CDX2 antibody from Biogenex Laboratories, Inc.